January 23, 2018 08:00 AM ESTUpdated 11:41 AM

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, CRISPR

John Carroll

Editor & Founder

Novartis vet Usman “Oz” Azam and Penn researcher Carl June are two of the ultimate insiders in the CAR-T revolution. They each played prominent roles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, CRISPR

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Al­lied with Penn, Tmu­ni­ty’s cell ther­a­py pi­o­neers bag $100M mega-round to back a break­through quest on CAR-T, CRISPR

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, CRISPR